Back to top
more

Geron (GERN)

(Delayed Data from NSDQ)

$4.27 USD

4.27
13,018,136

+0.05 (1.18%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $4.23 -0.04 (-0.94%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Top Ranked Momentum Stocks to Buy for June 9th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 9th.

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

by Zacks Equity Research

Is (GERN) Outperforming Other Medical Stocks This Year?

Top Ranked Momentum Stocks to Buy for June 5th

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 5th.

Top Ranked Momentum Stocks to Buy for June 2nd

by Zacks Equity Research

Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, June 2nd.

Geron (GERN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 11.11% and -52.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Geron (GERN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Geron (GERN) reports encouraging fourth-quarter 2019 results. Operating expenses increase on a year-over-year basis.

Geron (GERN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of 25.00% and 26.67%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Agios' Tibsovo Wins FDA's Breakthrough Therapy Tag for MDS

by Zacks Equity Research

The FDA bestows a Breakthrough Therapy status on Agios' (AGIO) leukemia drug Tibsovo for treating relapsed/refractory myelodysplastic syndrome in adult patients with a susceptible IDH1 mutation.

Geron (GERN) Up 2.4% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Geron (GERN) Stock Surges 40% YTD: What's Driving the Rally?

by Zacks Equity Research

Geron's (GERN) telomerase inhibitor, imetelstat, is being evaluated in two clinical studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

Geron (GERN) Q3 Earnings Beat Estimates, Stock Gains 4.1%

by Zacks Equity Research

Geron (GERN) reports encouraging third-quarter 2019 results. Operating expenses increase on a year-over-year basis.

Earnings Preview: Geron (GERN) Q3 Earnings Expected to Decline

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Geron Starts Enrollment in Phase III MDS Study on Imetelstat

by Zacks Equity Research

Geron enrolls first patient in the late-stage IMerge study to evaluate imetelstat in myelodysplastic syndromes.

Geron's Imetelstat Gets Fast Track Status for Myelofibrosis

by Zacks Equity Research

Geron's (GERN) sole pipeline candidate, imetelstat, receives Fast Track designation from the FDA for treating relapsed or refractory myelofibrosis. Shares up.

Why Is Geron (GERN) Up 21.7% Since Last Earnings Report?

by Zacks Equity Research

Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Geron (GERN) Stock Rises 40% in 2019 So Far: Here's Why

by Zacks Equity Research

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late-stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

Geron (GERN) Stock Up Despite Q2 Earnings & Sales Miss

by Zacks Equity Research

Geron (GERN) posts a wider-than-expected loss in second-quarter 2019. Operating expenses increase on a year-over-year basis.

Geron (GERN) Reports Q2 Loss, Misses Revenue Estimates

by Zacks Equity Research

Geron (GERN) delivered earnings and revenue surprises of -33.33% and -49.75%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Geron (GERN) Q2 Earnings Expected to Decline

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Is Geron (GERN) Down 22% Since Last Earnings Report?

by Zacks Equity Research

Geron (GERN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Geron Stock Up More Than 50% in 2019 So Far: Here's Why

by Zacks Equity Research

Geron (GERN) telomerase inhibitor, imetelstat, is being evaluated in two late stage studies for patients with MDS and myelofibrosis. The candidate is progressing well in clinical studies.

Geron's (GERN) Q1 Earnings Beat, Revenues Miss, Stock Up

by Zacks Equity Research

Geron (GERN) posts narrower-than-expected loss in first-quarter 2019 but misses on revenues. Operating expenses increase on a year-over-year basis.

Analysts Estimate Geron (GERN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.